These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28703529)

  • 21. Tocilizumab for multirefractory adult-onset Still's disease.
    De Bandt M; Saint-Marcoux B
    Ann Rheum Dis; 2009 Jan; 68(1):153-4. PubMed ID: 19088261
    [No Abstract]   [Full Text] [Related]  

  • 22. [Immunotherapy using IL-6 receptor as the target].
    Nishimoto N
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):399-404. PubMed ID: 18974624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role and therapeutic targeting of IL-6 in rheumatoid arthritis.
    Narazaki M; Tanaka T; Kishimoto T
    Expert Rev Clin Immunol; 2017 Jun; 13(6):535-551. PubMed ID: 28494214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody.
    Nishimoto N; Nakahara H; Yoshio-Hoshino N; Mima T
    Arthritis Rheum; 2008 Apr; 58(4):1197-200. PubMed ID: 18383395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
    Tanaka T; Hagihara K; Shima Y; Narazaki M; Ogata A; Kawase I; Kishimoto T
    Rheumatology (Oxford); 2010 Apr; 49(4):824-6. PubMed ID: 20008092
    [No Abstract]   [Full Text] [Related]  

  • 26. Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy.
    Snir A; Kessel A; Haj T; Rosner I; Slobodin G; Toubi E
    Clin Exp Rheumatol; 2011; 29(4):697-700. PubMed ID: 21813064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.
    Paul-Pletzer K
    Drugs Today (Barc); 2006 Sep; 42(9):559-76. PubMed ID: 17028666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Refractory neuro-Behçet treated by tocilizumab: a case report.
    Urbaniak P; Hasler P; Kretzschmar S
    Clin Exp Rheumatol; 2012; 30(3 Suppl 72):S73-5. PubMed ID: 23020826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of IL-6 and Development of Anti-IL-6R Antibody.
    Kishimoto T
    Keio J Med; 2019; 68(4):96. PubMed ID: 31875623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Anti-IL-6 receptor antibody].
    Nishimoto N
    Nihon Rinsho; 2005 May; 63 Suppl 5():723-7. PubMed ID: 15954436
    [No Abstract]   [Full Text] [Related]  

  • 31. The clinical efficacy of tocilizumab in rheumatoid arthritis.
    Mircic M; Kavanaugh A
    Drugs Today (Barc); 2009 Mar; 45(3):189-97. PubMed ID: 19436841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tocilizumab in refractory adult Still's disease.
    Puéchal X; DeBandt M; Berthelot JM; Breban M; Dubost JJ; Fain O; Kahn JE; Lequen L; Longy-Boursier M; Perdriger A; Schaeverbeke T; Toussirot E; Sibilia J;
    Arthritis Care Res (Hoboken); 2011 Jan; 63(1):155-9. PubMed ID: 20740616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody.
    Mihara M; Ohsugi Y; Kishimoto T
    Biofactors; 2009; 35(1):47-51. PubMed ID: 19319845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
    Tanaka T; Kuwahara Y; Shima Y; Hirano T; Kawai M; Ogawa M; Arimitsu J; Hagihara K; Narazaki M; Ogata A; Kawase I; Kishimoto T
    Arthritis Rheum; 2009 Dec; 61(12):1762-4. PubMed ID: 19950316
    [No Abstract]   [Full Text] [Related]  

  • 35. [New therapeutic strategy for autoimmune and chronic inflammatory disease based on clinical results using IL-6 blocking therapy with a humanized anti-IL-6 receptor antibody].
    Yoshizaki K
    Yakugaku Zasshi; 2009 Jun; 129(6):667-74. PubMed ID: 19483409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subcutaneous tocilizumab for the treatment of rheumatoid arthritis.
    Mitchell E; Jones G
    Expert Rev Clin Immunol; 2016; 12(2):103-14. PubMed ID: 26629984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antagonists of interleukin-6 (tocilizumab), in adult refractory still disease].
    Sekkach Y; Elqatni M; Khattabi AE; Fatihi J; Hammi S; Badaoui M; Elomri N; Mekouar F; Amezyane T; Abouzahir A; Ghafir D
    Presse Med; 2011; 40(7-8):e333-7. PubMed ID: 21550202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease.
    Iwamoto M; Nara H; Hirata D; Minota S; Nishimoto N; Yoshizaki K
    Arthritis Rheum; 2002 Dec; 46(12):3388-9. PubMed ID: 12483747
    [No Abstract]   [Full Text] [Related]  

  • 39. Humanized antihuman IL-6 receptor antibody, tocilizumab.
    Nishimoto N; Kishimoto T
    Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-6: a new therapeutic target.
    Smolen JS; Maini RN
    Arthritis Res Ther; 2006; 8 Suppl 2(Suppl 2):S5. PubMed ID: 16899109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.